These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3469100)

  • 1. AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML).
    Hagenbeek A; Martens AC
    Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1255-8. PubMed ID: 3469100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia.
    el-Beltagi HM; Martens AC; Lelieveld P; Haroun EA; Hagenbeek A
    Cancer Res; 1993 Jul; 53(13):3008-14. PubMed ID: 8319208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML).
    Hagenbeek A; Weiershausen U; Martens AC
    Leukemia; 1988 Apr; 2(4):226-30. PubMed ID: 3163079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryopreservation of autologous marrow grafts in acute leukemia: survival of in vivo clonogenic leukemic cells and normal hemopoietic stem cells.
    Hagenbeek A; Martens AC
    Leukemia; 1989 Jul; 3(7):535-7. PubMed ID: 2659904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia.
    el-Beltagi HM; Martens AC; Dahab GM; Hagenbeek A
    Leukemia; 1993 Nov; 7(11):1795-800. PubMed ID: 8231248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cyclophosphamide treatment of acute myelocytic leukemia. Studies in the BNML rat model.
    Hagenbeek A; Martens AC
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):763-9. PubMed ID: 6759141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model.
    Rozemuller H; Rombouts WJ; Touw IP; FitzGerald DJ; Kreitman RJ; Pastan I; Hagenbeek A; Martens AC
    Leukemia; 1996 Nov; 10(11):1796-803. PubMed ID: 8892684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia.
    Colly LP; van Bekkum DW; Hagenbeek A
    Leuk Res; 1984; 8(6):953-63. PubMed ID: 6595483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)).
    Martens AC; Van Bekkum DW; Hagenbeek A
    Leukemia; 1990 Apr; 4(4):241-57. PubMed ID: 2195239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo development of an acetyldinaline resistant subline of the BN rat acute myelocytic leukemia (BNML).
    el-Beltagi HM; Martens AC; Haroun EA; Hagenbeek A
    Leukemia; 1993 Aug; 7(8):1275-80. PubMed ID: 8350629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model.
    Vaughan WP; Holm C; Cordel K
    Cancer Chemother Pharmacol; 1989; 23(1):26-30. PubMed ID: 2909287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of normal hemopoietic stem cells during leukemia growth before and after induction of a complete remission. Studies in a rat model for acute myelocytic leukemia (BNML).
    Martens AC; Hagenbeek A
    Leuk Res; 1987; 11(5):453-9. PubMed ID: 3472017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells.
    Martens AC; Johnson RJ; Kaizer H; Hagenbeek A
    Exp Hematol; 1984 Sep; 12(8):667-71. PubMed ID: 6386506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP; Peters WG; Willemze R
    Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.
    Hagenbeek A; Martens AC
    Invest New Drugs; 1984; 2(2):237-43. PubMed ID: 6381383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML).
    Martens AC; van Bekkum DW; Hagenbeek A
    Int J Cell Cloning; 1990 Jan; 8(1):27-38. PubMed ID: 2403582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of doxorubicin for normal hematopoietic and acute myeloid leukemia cells of the rat.
    Sonneveld P; Mulder Ja; van Bekkum DW
    Cancer Chemother Pharmacol; 1981; 5(3):167-73. PubMed ID: 6945921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation of normal hemopoietic stem cells from clonogenic leukemic cells in a rat model for human acute myelocytic leukemia. II. Velocity sedimentation in combination with density gradient separation.
    Hagenbeek A; Martens AC
    Exp Hematol; 1981 Jul; 9(6):573-80. PubMed ID: 6943036
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
    Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A
    Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldehyde dehydrogenase involvement in a variant of the brown Norway rat acute myelocytic leukaemia (BNML) that acquired cyclophosphamide resistance in vivo.
    de Groot CJ; Martens AC; Hagenbeek A
    Eur J Cancer; 1994; 30A(14):2137-43. PubMed ID: 7857714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.